Key result
PCSK9 inhibitor therapy is linked to ~56% lower all-cause mortality in eligible patients.
Why the study?
Does PCSK9 inhibitor therapy improve biochemical, clinical, and economic outcomes in eligible patients in a real-world setting?
Cohort (n=5,298)
Yes
Does PCSK9 inhibitor therapy improve biochemical, clinical, and economic outcomes in eligible patients in a real-world setting?
Answers are grounded in this paper and cite their sources.
In a real-world setting, PCSK9 inhibitor therapy is associated with significant reductions in LDL-C, all-cause mortality, and hospitalizations, offsetting higher drug costs with savings in other healthcare services.
BACKGROUND: PCSK9 inhibitors (PCSK9i) in combination with high-dose statins can reduce LDL-cholesterol (LDL-C) levels by 50-60% over statin monotherapy. This analysis investigated biochemical (LDL-C reduction) and economic outcomes in Italian patients treated with PCSK9i or potentially eligible but untreated. METHODS: Administrative databases of healthcare institutions covering around 5 million residents were used to identify patients with PCSK9i prescriptions or potentially eligible-untreated patients between 2017 and Oct-2022. Outcomes were assessed during follow-up in cohorts balanced for baseline covariates by propensity score matching (PSM). RESULTS: After PSM-balancing, 2649 treated and 2649 potentially eligible-untreated patients were included: mean age 64.4-64.7 years, 70-68% males, 92-93% with hypertension, 24-25% with diabetes, and 87% with previous atherosclerotic/cardiovascular events. During follow-up, PCSK9i-treated patients versus untreated/eligible showed a reduction of LDL-C levels (68.9±43.9 vs. 100.4±34.6 mg/dL, P<0.0001), hospitalization rates for heart attack (4.5% vs. 6.8%, P=0.0069), heart failure (4.5% vs. 6.6%, P=0.010), and lower all-cause mortality (3.2% vs. 9.5%, P<0.0001). The multivariate Cox model confirmed that eligible-untreated patients had a more than doubled mortality risk compared to the PCSK9i-treated ones (HR: 2.291, 95%CI: 1.651-3.178, P<0.0001). Although mean annualized total healthcare costs were higher in PCSK9i-treated versus untreated/eligible patients (€6745 vs. €4343, P<0.0001), because of the higher drug costs, PCSK9i therapy was associated with reduced expenses for hospitalizations (€1113 vs. €1687, P<0.0001) and specialist outpatient services (€386 vs. €787, P<0.0001). CONCLUSIONS: The real-world analysis suggests that therapy with PCSK9i resulted in reduced LDL-C levels, lower mortality rates and cost savings for hospitalizations and specialist services.
No takes yet. Share an insight, caveat, or question.
Dovizio et al. (2025) conducted a cohort in Hypercholesterolemia / High cardiovascular risk (n=5,298). PCSK9 inhibitors vs. Potentially eligible but untreated patients was evaluated on All-cause mortality (HR 2.291, 95% CI 1.651-3.178, p=<0.0001). PCSK9 inhibitor therapy was associated with lower all-cause mortality compared to eligible untreated patients (3.2% vs 9.5%; untreated vs treated HR 2.291, 95% CI 1.651-3.178, P<0.0001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: